Search Results
Jun 21, 2025, 08:38 ET New data from phase III trial confirms efficacy of Vyepti® (eptinezumab) in Asian population with chronic migraine
(IV) infusion.2 About Vyepti® (eptinezumab) Eptinezumab is a humanized monoclonal antibody that binds to calcitonin gene-related peptide (CGRP) which was intentionally designed for IV administration. The efficacy and safety of eptinezumab was evaluated in two phase III
More news about: H. Lundbeck A/S
Jun 20, 2025, 10:58 ET 2024 Cell and Gene Therapy Market Set for Breakthrough Growth, Says BCC Research
"Comprehensive Review Highlights Market Growth, Innovation, and Investment Trends Driving the Future of Cell and Gene Therapy Tools, Biomanufacturing, and Gene Synthesis" BOSTON,
More news about: BCC Research LLC
Jun 20, 2025, 09:31 ET Rocket Pharmaceuticals, Inc. Stockholders with Large Losses Should Contact Robbins LLP for Information About the Class Action Against RCKT
2025 and May 26, 2025. Rocket is a fully integrated, late-stage biotechnology company focused on the development of gene therapies, with direct on-target mechanism of action and clear clinical endpoints, for rare and devastating diseases.
More news about: Robbins LLP
Jun 20, 2025, 07:15 ET 13 Press Releases You Need to See This Week
acquire Verve Therapeutics to advance one-time treatments for people with high cardiovascular riskVerve is developing a pipeline of gene editing medicines designed to address the drivers of atherosclerotic cardiovascular disease (ASCVD) through treatments that may only need to be given
More news about: PR Newswire
Jun 20, 2025, 04:30 ET Gene Solutions 加強在中國的精準腫瘤學戰略合作佈局
雄安妙心生物科技有限公司分別簽署兩份戰略合作備忘錄（MOU）。此次合作標誌著 Gene Solutions 在中國市場精準腫瘤學領域的重點拓展，涵蓋技術引入、科研探索及創新癌症檢測平台的本地化部署。 這些合作進一步鞏固了 Gene Solutions 長期支持中國醫療創新生態系統的承諾，提供先進、臨床驗證的癌症早篩與監測工具。 早篩網：通過生態系統聯動推動早篩普及 Gene Solutions 與早篩網達成戰略業務聯盟，雙方將共同推動先進癌症早篩技術在中國的引入、推廣及合規商業化。
More news about: Gene Solutions Genomics Pte Ltd
Jun 20, 2025, 02:54 ET MGI Tech Receives CE Mark for DNBSEQ-T1+ Sequencer
after-sales service facilities globally. MGI stands out as one of the few companies capable of independently developing and mass-producing clinical-grade gene sequencers with varying throughput capacities, ranging from Gb to Tb levels. With unparalleled expertise, cutting-edge products, and a commitment to
More news about: MGI Tech
Jun 19, 2025, 17:46 ET HER2-low Cancers Market Set to Register Immense Growth at a CAGR of 9.4% During the Study Period (2020-2034) | DelveInsight
by the ERBB2 gene, playing a crucial role in cell growth, differentiation, and survival. It is part of the epidermal growth factor receptor family and is typically analyzed using molecular techniques. HER2 protein overexpression is assessed through immunohistochemistry (IHC), while gene amplification
More news about: DelveInsight Business Research, LLP
Jun 19, 2025, 14:36 ET Biological Safety Cabinets Market to Reach USD 448.4 Million by 2032, Driven by Rising Biosafety Standards and Research Demand
Administration (FDA) received over 1,300 IND applications, a 15% increase compared to pre-pandemic levels. This surge is mirrored by the growth in cell and gene therapy clinical trials, which require stringent contamination control. Additionally, the global rise in vaccine development projects—over 300 COVID-19
More news about: Credence Research Inc.
Jun 19, 2025, 13:46 ET Swim with a Purpose: CLASH Endurance Announces New Charity Swim Events with Swim Across America
success rate treating MMRd cancers with immunotherapy alone. Swim Across America also recently awarded the first-of-their-kind gene editing innovation grants to Alliance for Cancer Gene Therapy and Dana-Farber Cancer Institute to advance safer, more effective targeted treatments. "Swim Across America,
More news about: Clash USA, LLC
Jun 19, 2025, 10:54 ET Zemcelpro® (UM171 Cell Therapy) receives positive CHMP opinion for treatment of blood cancer patients without access to suitable donor cells
haematopoietic stem cells (HSCs) from any source and counteracting the effects of culture or gene editing induced stress. ExCellThera partners with biopharmas to help them develop best-in-class cell and gene therapies by leveraging the technologies that form the Enhance™ platform, including
More news about: ExCellThera
Jun 19, 2025, 10:26 ET Zemcelpro® (UM171 Cell Therapy) receives positive CHMP opinion for treatment of blood cancer patients without access to suitable donor cells
haematopoietic stem cells (HSCs) from any source and counteracting the effects of culture or gene editing induced stress. ExCellThera partners with biopharmas to help them develop best-in-class cell and gene therapies by leveraging the technologies that form the Enhance™ platform, including
More news about: ExCellThera
Jun 19, 2025, 10:01 ET Hemostats Market Set to Attain Valuation of US$ 4,839 Million By 2033 Says Astute Analytica
Cytology Testing, Genetic Testing, Drug of Abuse Testing); Application (Bioanalytical & Lab Chemistry Services, Toxicology Testing Services, Cell & Gene Therapy Related Services, Preclinical & Clinical Trial Related Services, Drug Discovery & Development Related Services, Others); End Users (Hospitals,
More news about: Astute Analytica
Jun 18, 2025, 12:03 ET 'Functional Unemployment' Increases in May, Says Ludwig Institute
@LISEP_org. About Gene LudwigIn addition to his role as LISEP chair, Gene Ludwig is a managing partner of Canapi LLC, a financial technology venture fund. He is the founder
More news about: Ludwig Institute for Shared Economic Prosperity
Jun 18, 2025, 12:00 ET Parent Project Muscular Dystrophy Hosts 2025 Annual Conference in Las Vegas, Nevada
neuromuscular care, cardiology, exercise, and physical therapy, as well as industry updates about emerging therapies for Becker.Exploring the gene therapy landscape; understanding immune responses, how we got here and where we're going.Cardiac and neuromuscular care for carriers, as well
More news about: Parent Project Muscular Dystrophy (PPMD)
Jun 18, 2025, 11:30 ET RCKT INVESTOR NOTICE: Rocket Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
[email protected]. CASE ALLEGATIONS: Rocket Pharmaceuticals operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. The Rocket Pharmaceuticals class action lawsuit alleges that defendants provided
More news about: Robbins Geller Rudman & Dowd LLP
Jun 18, 2025, 11:00 ET Oligonucleotide Synthesis Market is expected to generate a revenue of USD 5.75 Billion by 2031, Globally, at 10.49% CAGR: Verified Market Research®
moreCompetitive Landscape – Profiles of top players and their strategic initiativesBiotech R&D Investment – Expanding gene editing and RNA research increases synthesis requirementsAdvanced Diagnostic Tools – Oligos enable accurate detection of genetic and
More news about: Verified Market Research
Jun 18, 2025, 10:36 ET Pierre Fabre Laboratories Begins Next Chapter in Secaucus, NJ
subsidiaries. Pierre Fabre is the world's second-largest dermo-cosmetics manufacturer and a global player in oncology, cell & gene therapy, rare disease and dermatology. This strategic move in the US marks a pivotal moment in the company's growth strategy, underscoring its strong
More news about: Avène USA
Jun 18, 2025, 10:30 ET Sterile Medical Packaging Market to Hit USD 44.6 Billion by 2029 | Key Drivers: Pharma Growth, Infection Control: Valuates Reports
packaging solutions. The rapid expansion of the biopharmaceutical sector is reshaping the sterile medical packaging landscape. Biologics, vaccines, gene therapies, and cell-based treatments require precise packaging solutions that ensure sterility, stability, and protection from light and oxygen. These
More news about: Valuates Reports
Jun 18, 2025, 07:15 ET AbbVie Announces New Data Demonstrating Atogepant (QULIPTA® / AQUIPTA®) Achieves Superiority Across All Endpoints in Phase 3 Head-to-Head Study Compared to Topiramate for Migraine Prevention
month.1 The study met the primary endpoint of treatment discontinuation due to adverse events (AEs), demonstrating that atogepant, a calcitonin gene-related peptide (CGRP) receptor antagonist, had fewer discontinuations due to AEs than topiramate, an anticonvulsant medication also approved for migraine
More news about: AbbVie
Jun 18, 2025, 07:05 ET Social and Economic Factors Explain Why Black Patients Lose Less Weight After Bariatric Surgery than Other Groups
analyzing data from the study participants to explore additional biological factors that may influence weight loss surgery outcomes, including changes in gene expression and the microbiome. "As a clinical community, we have to be honest that these differences exist, as well as reinforce the importance
More news about: NYU Langone Health System
Jun 18, 2025, 07:00 ET KLOTHO NEUROSCIENCES (KLTO) ANNOUNCES MUTUAL TERMINATION OF SHARE EXCHANGE AGREEMENT WITH SKYBELL TECHNOLOGIES (SKYBELL), TO CONTINUE ITS FOCUS ON THERAPEUTICS AND LONGEVITY PROGRAMS
company focused on the development of innovative, disease-modifying cell and gene therapies using an important human protein derived from the Company's patented form of the "anti-aging" human Klotho gene (s-KL) and their novel gene promoters and delivery systems to transform and improve the treatment of
More news about: Klotho Neurosciences, Inc.
Jun 18, 2025, 06:00 ET Nob Hill Therapeutics Expands Strategic Advisory Board with Two Distinguished Leaders in Respiratory Drug Development and Pulmonary Medicine
company with a significant commitment to respiratory medicine). Prior to this, he served as CEO of Topigen Pharmaceuticals (a clinical stage biotech with gene silencing inhaled therapeutics), and has worked for pSivida (a NASDAQ-listed drug delivery company) and Innovata Biomed (a company focused on dry powder
More news about: Nob Hill Therapeutics
Jun 17, 2025, 11:30 ET Independence Blue Cross and Children's Hospital of Philadelphia sign new agreement that reflects their joint commitment to children's health in the region
Advanced Network for Gene-Based Therapeutics, which was established to help IBX members access potentially life-changing gene-based therapies from best-in-class health care institutions, like CHOP. "Improving access
More news about: Independence Blue Cross
Jun 17, 2025, 10:55 ET King Faisal Specialist Hospital & Research Centre and Germfree Laboratories Announce Landmark Advanced Therapy Manufacturing Campus in Riyadh
said Kevin Kyle, CEO of Germfree Laboratories. "Together, we are building much more than a facility for Cell & Gene Therapy manufacturing, we're building a turnkey, scalable platform for discovery and delivery of curative therapies for the people of Saudi
More news about: Germfree Laboratories LLC
Jun 17, 2025, 10:45 ET Bioprocessing Equipment Market to Reach USD 162.2 Billion by 2035, Says Meticulous Research®
pharmaceuticals, with monoclonal antibodies, cell and gene therapies, and recombinant proteins leading therapeutic innovation across oncology, immunology, and rare disease applications. Breakthrough therapies including CAR-T cell treatments, mRNA vaccines, and gene editing applications require sophisticated
More news about: Meticulous Market Research Pvt. Ltd.